Table 1.

Descriptive characteristics of the total study population (n = 81) as well as the subgroups “completed”, with no change of therapy for one year (n = 68) and “therapy changed” (n = 13). Data shown as mean value ± standard deviation and percentages in brackets

	Total (n = 81)	Completed (n = 68)	Therapy Change/Stop (n = 13)
Age – yr	49.72 ± 14,2	49.81 ± 12.58	46.46 ± 18.4
Sex, Female, n (%)	39 (48.15%)	32 (47.06%)	7 (53.85%)
Time since most recent polyp surgery (y)	4.44 ± 3.9	4.39 ± 3.65	4.85 ± 5.65
Nasal-Polyp surgery
≥ 1 previous surgery	81 (100%)	68 (100%)	13 (100%)
≥ 3 previous surgery	52 (64.2%)	45 (66.18%)	7 (53.85%)
≥ 5 previous surgery	11 (13.6%)	9 (13.24%)	2 (15.38%)
Systemic corticosteroid in the last 2	60 (74.1%)	49 (72.1%)	11 (84.6%)
Aspirin desensitization	11 (13.58%)	9 (13.24%)	2 (15.38%)
SNOT-22 total score before therapy	55.04 ± 16.9	53.74 ± 17.62	60.38 ± 11.17
VAS nasal congestion before therapy (scale 0–10)	6.36 ± 2.6	6.32 ± 2.66	6.28 ± 2.25
GINA Score in patients with comorbid asthma before therapy	2.7 ± 1.07	2.71 ± 1.07	2.63 ± 1.19
NPS before therapy (scale 0–8)	5.31 ± 1.87	5.44 ± 1.79	4.62 ± 2.18
Smell-VAS initial	9.14 ± 1.79	9.16 ± 1.85	9.03 ± 1.51
Smell Test Score (Sniffin’ sticks screening Test, Scale 0–12)	2.47 ± 2.79	2.26 ± 2.72	2.85 ± 3.05
Baseline Blood IgE (IU/ml)	267.19 ± 405.64	251.43 ± 339.46	260.81 ± 741.37
Baseline Blood eosinophils (n/μl)	472.49 ± 401.15	475.51 ± 397.39	456.92 ± 436.51
Other biologicals before treatment with dupilumab	3 (3.7%)	3 (4.41%)	0 (0%)
Comorbidity, n (%)	78 (96.3%)	67 (98.53%)	11 (84.62%)
Non	3 (3.7%)	1 (1.47%)	2 (15.38%)
Allergic Rhinitis intermittent	24 (29.63%)	19 (27.94%)	5 (38.46%)
Allergic Rhinitis persistent	18 (22.22%)	18 (26.47%)	0 (0%)
Other Allergy (Food/Medication)	19 (23.46%)	14 (20.59%)	5 (38.46%)
NSAID intolerance	36 (44.44%)	30 (44.12%)	6 (46.15%)
Asthma	61 (75.31%)	53 (77.94%)	8 (61.54%)